Swissmedic approves Beyfortus for RSV prophylaxis in newborns, infants and young children
Bern, 28.12.2023 - Following a thorough review, Swissmedic has authorised the medicinal product Beyfortus from marketing authorisation holder Sanofi-Aventis (Suisse) SA. Beyfortus is used for the prophylaxis of lower respiratory tract disease caused by the respiratory syncytial virus (RSV).